News Center


ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Add...

ACELYRIN, INC., a late- stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the closing of its previously announced upsized initial public offering

Read More Arrow purple
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks
Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer
ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
Izokibep - Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
Izokibep for the treatment of moderate-to-severe plaque psoriasis - a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa